多肽降压药是近年发展的一类抗高血压药,其主要作用是(图1)抑制血管紧张素转化酶,使体内血管紧张素Ⅱ(ATⅡ)生成减少使血压下降。血管紧张素转化酶抑制剂SQ14225已成为降压作用明显、口服有效的一类新型降压药。本文研究的药物系本院制药工艺教研室所合成的新的多肽药物。本文应用代号为 SP101,102,103,104和 SP210,211,212。现将各药降压作用的比较研究报告如下。 Peptide antihypertensive drugs in recent years is a class of antihypertensive drugs, its main role is (Figure 1) inhibition of angiotensin converting enzyme, so that the formation of angiotensin Ⅱ (AT Ⅱ) in vivo to reduce blood pressure. Angiotensin converting enzyme inhibitor SQ14225 has become a class of antihypertensive drugs with obvious antihypertensive effect and orally effective. The drug studied in this article is a new peptide drug synthesized by the Institute of Pharmaceutical Technology. This application code-named SP101,102,103,104 and SP210,211,212. Now the antihypertensive effect of each drug comparative studies are as follows.